No profile data available.
Abivax Société Anonyme (ABVX) is a healthcare company in the digestive system treatment drugs industry, based in Paris, France, with about 98 full-time employees.
It reported revenue of 0 EUR for fiscal year 2025, and net income of -336.10 million EUR. In Q2 2026 (the quarter ended June 30, 2026) revenue was 0 EUR. Its market capitalization was $7.69 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases.
Abivax Société Anonyme reported 0 EUR in revenue for fiscal year 2025. In Q2 2026 revenue was 0 EUR.
$7.69 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (digestive system treatment drugs) include Spyre Therapeutics, Inc. (SYRE), Ironwood Pharmaceuticals, Inc. (IRWD), Phathom Pharmaceuticals, Inc. (PHAT), Palisade Bio, Inc. (PALI).